These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28923647)

  • 1. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
    Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
    Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
    Kim JH; Goulston C; Sanders S; Lampas M; Zangari M; Tricot G; Hanson KE
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1753-8. PubMed ID: 22728249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients.
    Annibali O; Piccioni L; Tomarchio V; Circhetta E; Sarlo C; Franceschini L; Cantonetti M; Rizzo E; Angeletti S; Tirindelli MC; Scagnolari C; Statzu M; Avvisati G; Riva E
    PLoS One; 2018; 13(7):e0200221. PubMed ID: 30036376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
    Sharma SK; Kumar S; Agrawal N; Singh L; Mukherjee A; Seth T; Mishra P; Mathur S; Dar L; Mahapatra M
    J Infect Dev Ctries; 2013 Dec; 7(12):1003-7. PubMed ID: 24334950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma.
    Fassas AB; Bolaños-Meade J; Buddharaju LN; Rapoport A; Cottler-Fox M; Chen T; Lovchik JC; Cross A; Tricot G
    Br J Haematol; 2001 Jan; 112(1):237-41. PubMed ID: 11167810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
    Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
    Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
    Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
    Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
    Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
    JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
    Hussein AA; Al-Antary ET; Najjar R; Al-Hamdan DS; Al-Zaben A; Frangoul H
    Pediatr Blood Cancer; 2015 Jun; 62(6):1099-101. PubMed ID: 25346146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y
    Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
    Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
    Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.
    Reed DR; Petroni GR; West M; Jones C; Alfaraj A; Williams PG; DeGregory K; Grose K; Monson S; Varadarajan I; Volodin L; Donowitz GR; Kindwall-Keller TL; Ballen KK
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):61-69. PubMed ID: 36634280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B; Rosamilio R; Giudice V; Pepe S; Zeppa P; Esposiito S; Pezzullo L; Rocco M; Montuori N; Selleri C
    Infez Med; 2012; 20 Suppl 2():26-34. PubMed ID: 23042003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.